EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Larotrectinib for Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric NTRK Fusion–Positive Solid Tumors (Children's Oncology Group ADVL1823)

Theodore W Laetsch iD, Stephan Voss iD, Kathleen Ludwig, David Hall iD, Donald A Barkauskas iD, Steven G DuBois iD, Joan Ronan, Erin R Rudzinski, Amanda Memken iD, Krystal Robinson, Joel Sorger, Joel M Reid iD und 5 weitere

Journal of Clinical Oncology · 2025-04 · 43 (10) · 1188-1197

DOI: 10.1200/jco-24-01854 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Clinical Oncology, 2025-04. Verfasst von Theodore W Laetsch und 16 weiteren Autor:innen. Beteiligte Einrichtung: Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA. Hauptthemen laut MEDLINE: Fibrosarcoma, Oncogene Proteins, Fusion, Protein Kinase Inhibitors, Pyrazoles. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The TRK inhibitor larotrectinib is US Food and Drug Administration approved for NTRK fusion–positive solid tumors that lack a satisfactory alternative or have progressed after treatment but has not been systematically studied as a frontline therapy with a defined duration of treatment. ADVL1823 evaluated larotrectinib in patients with newly diagnosed NTRK fusion–positive solid tumors with response-adapted duration of therapy and local control. METHODS Patients received larotrectinib twice daily in 28-day cycles for a predefined duration of treatment, ranging from 6 to 26 cycles depending on response to therapy and surgical resectability. The primary end point was the objective response rate (ORR) within six cycles in patients with infantile fibrosarcoma (IFS); patients with other histologic diagnoses were analyzed in a separate cohort. Secondary objectives included event-free survival (EFS) and overall survival (OS). RESULTS Thirty-three patients were enrolled: 18 with IFS and 15 with other solid tumors. The ORR within six cycles was 94% (17/18; 95% adjusted CI, 72.7 to 98.6) among children with IFS and 60% (9/15; 95% CI, 32.3 to 83.7) among children with other solid tumors. Six percent (2/33; 95% CI, 0.7 to 22.2) patients developed progressive disease while on therapy. Two-year EFS and OS among these groups were 82.2% (95% CI, 54.3 to 93.9) and 93.8% (95% CI, 63.2 to 99.1) for IFS and 80% (95% CI, 50.0 to 93.1) and 93.3% (95% CI, 61.3 to 99.0) for other solid tumors, respectively. Patients undergoing surgical resection of their tumor had prolonged EFS, with only 1 of 16 such patients experiencing disease progression. Four of 33 patients had dose-limiting toxicities. CONCLUSION Larotrectinib is highly active in patients with newly diagnosed NTRK fusion–positive solid tumors. Larotrectinib should be a frontline option for patients with IFS and other NTRK fusion–positive solid tumors. Local control with surgical resection remains important in the treatment of patients with IFS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FibrosarcomaOncogene Proteins, FusionProtein Kinase InhibitorsPyrazolesPyrimidinesReceptor, trkAReceptor, trkBAdolescentChildChild, PreschoolFemaleHumansInfantMaleReceptor, trkC

Substanzen

larotrectinibOncogene Proteins, FusionProtein Kinase InhibitorsPyrazolesPyrimidinesReceptor, trkAReceptor, trkBReceptor, trkC

Autor:innen und Institutionen

  • Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA.
  • Department of Radiology, Dana-Farber Cancer Institute, Boston, MA.
  • University of Texas Southwestern, Dallas, TX.
  • Children's Oncology Group Statistical Center, Monrovia, CA.
  • Department of Population and Public Health Sciences, Keck School of Medicine of the University of Southern California, Los Angeles, CA.
  • Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA.

ORCID-Profile: Theodore W Laetsch, Stephan Voss, David Hall, Donald A Barkauskas, Steven G DuBois, Amanda Memken, Joel M Reid, Brian D Crompton, Alanna J Church, Elizabeth Fox, Brenda J Weigel

Förderung

  • NCI NIH HHS

Zitieren

APA

Laetsch, T. W., Voss, S., Ludwig, K., Hall, D., Barkauskas, D. A., DuBois, S. G., Ronan, J., Rudzinski, E. R., Memken, A., Robinson, K., Sorger, J., Reid, J. M., Bhatla, T., Crompton, B. D., Church, A. J., Fox, E., & Weigel, B. J. (2025). Larotrectinib for Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric NTRK Fusion–Positive Solid Tumors (Children's Oncology Group ADVL1823). Journal of Clinical Oncology, 43(10), 1188-1197. https://doi.org/10.1200/jco-24-01854

Vancouver

Laetsch TW, Voss S, Ludwig K, Hall D, Barkauskas DA, DuBois SG, et al. Larotrectinib for Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric NTRK Fusion–Positive Solid Tumors (Children's Oncology Group ADVL1823). Journal of Clinical Oncology. 2025;43(10):1188-1197. doi:10.1200/jco-24-01854

BibTeX
@article{Laetsch2025,
  author = {Laetsch, Theodore W and Voss, Stephan and Ludwig, Kathleen and Hall, David and Barkauskas, Donald A and DuBois, Steven G and Ronan, Joan and Rudzinski, Erin R and Memken, Amanda and Robinson, Krystal and Sorger, Joel and Reid, Joel M and Bhatla, Teena and Crompton, Brian D and Church, Alanna J and Fox, Elizabeth and Weigel, Brenda J},
  title = {Larotrectinib for Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric NTRK Fusion–Positive Solid Tumors (Children's Oncology Group ADVL1823)},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {10},
  pages = {1188--1197},
  doi = {10.1200/jco-24-01854}
}
Kostenlos starten →